The Role of CtBP1 in Oncogenic Processes and Its Potential As a Therapeutic Target

Overview

Journal Mol Cancer Ther

Date 2017 Jun 4

PMID 28576945

Citations 49

Authors

Melanie A Blevins

Mingxia Huang

Rui Zhao

Affiliations

Soon will be listed here.

Abstract

Transcriptional corepressor proteins have emerged as an important facet of cancer etiology. These corepressor proteins are often altered by loss- or gain-of-function mutations, leading to transcriptional imbalance. Thus, research directed at expanding our current understanding of transcriptional corepressors could impact the future development of new cancer diagnostics, prognostics, and therapies. In this review, our current understanding of the CtBP corepressors, and their role in both development and disease, is discussed in detail. Importantly, the role of CtBP1 overexpression in adult tissues in promoting the progression of multiple cancer types through their ability to modulate the transcription of developmental genes ectopically is explored. CtBP1 overexpression is known to be protumorigenic and affects the regulation of gene networks associated with "cancer hallmarks" and malignant behavior, including increased cell survival, proliferation, migration, invasion, and the epithelial-mesenchymal transition. As a transcriptional regulator of broad developmental processes capable of promoting malignant growth in adult tissues, therapeutically targeting the CtBP1 corepressor has the potential to be an effective method for the treatment of diverse tumor types. Although efforts to develop CtBP1 inhibitors are still in the early stages, the current progress and the future perspectives of therapeutically targeting this transcriptional corepressor are also discussed. .

Citing Articles

Identification of novel diagnostic and prognostic microRNAs in sarcoma on TCGA dataset: bioinformatics and machine learning approach.

Rahmati R, Zarimeidani F, Ahmadi F, Yousefi-Koma H, Mohammadnia A, Hajimoradi M Sci Rep. 2025; 15(1):7521.

PMID: 40032929 PMC: 11876432. DOI: 10.1038/s41598-025-91007-x.

Identification of HES4 as a novel prognostic marker and therapeutic target in hepatocellular carcinoma.

Liu Y, Shen Y, Luo P, Wu S, Wang Y, Deng J Discov Oncol. 2025; 16(1):156.

PMID: 39934570 PMC: 11813838. DOI: 10.1007/s12672-025-01915-7.

TOP2A Promotes Proliferation, Migration, and Inflammatory Response in M5-Treated Keratinocytes by Binding CTBP1 to Activate Wnt/β-Catenin Signaling.

Yang Y, Liu S, Xiao X Cell Biochem Biophys. 2024; .

PMID: 39565516 DOI: 10.1007/s12013-024-01620-2.

C-Terminal Binding Protein: Regulator between Viral Infection and Tumorigenesis.

Huang M, Li Y, Li Y, Liu S Viruses. 2024; 16(6).

PMID: 38932279 PMC: 11209466. DOI: 10.3390/v16060988.

PNSC928, a plant-derived compound, specifically disrupts CtBP2-p300 interaction and reduces inflammation in mice with acute respiratory distress syndrome.

Li F, Yan W, Dong W, Chen Z, Chen Z Biol Direct. 2024; 19(1):48.

PMID: 38902802 PMC: 11191317. DOI: 10.1186/s13062-024-00491-0.

References

Deng Y, Liu J, Han G, Lu S, Wang S, Malkoski S . Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. Oncogene. 2010; 29(50):6603-8. PMC: 3081720. DOI: 10.1038/onc.2010.406. View

Thio S, Bonventre J, Hsu S . The CtBP2 co-repressor is regulated by NADH-dependent dimerization and possesses a novel N-terminal repression domain. Nucleic Acids Res. 2004; 32(5):1836-47. PMC: 390340. DOI: 10.1093/nar/gkh344. View

Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J . A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res. 2010; 38(Web Server issue):W695-9. PMC: 2896090. DOI: 10.1093/nar/gkq313. View

Kim J, Cho E, Kim S, Youn H . CtBP represses p300-mediated transcriptional activation by direct association with its bromodomain. Nat Struct Mol Biol. 2005; 12(5):423-8. DOI: 10.1038/nsmb924. View

Talbot L, Bhattacharya S, Kuo P . Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol. 2012; 3(2):117-36. PMC: 3388731. View

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

Grooteclaes M, Deveraux Q, Hildebrand J, Zhang Q, Goodman R, Frisch S . C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc Natl Acad Sci U S A. 2003; 100(8):4568-73. PMC: 153596. DOI: 10.1073/pnas.0830998100. View

Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M . DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005; 24(14):2375-85. DOI: 10.1038/sj.onc.1208429. View

Kovi R, Paliwal S, Pande S, Grossman S . An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ. 2009; 17(3):513-21. PMC: 2924672. DOI: 10.1038/cdd.2009.140. View

10.

Sutrias-Grau M, Arnosti D . CtBP contributes quantitatively to Knirps repression activity in an NAD binding-dependent manner. Mol Cell Biol. 2004; 24(13):5953-66. PMC: 480900. DOI: 10.1128/MCB.24.13.5953-5966.2004. View

11.

Shi Y, Sawada J, Sui G, Affar E, Whetstine J, Lan F . Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature. 2003; 422(6933):735-8. DOI: 10.1038/nature01550. View

12.

Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B . Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol. 2008; 28(5):1528-40. PMC: 2258777. DOI: 10.1128/MCB.02061-07. View

13.

Lazo J, Nemoto K, Pestell K, Cooley K, Southwick E, Mitchell D . Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol. 2002; 61(4):720-8. DOI: 10.1124/mol.61.4.720. View

14.

Turner N, Tutt A, Ashworth A . Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004; 4(10):814-9. DOI: 10.1038/nrc1457. View

15.

Hilbert B, Grossman S, Schiffer C, Royer Jr W . Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design. FEBS Lett. 2014; 588(9):1743-8. PMC: 4072453. DOI: 10.1016/j.febslet.2014.03.026. View

16.

Ouyang J, Shi Y, Valin A, Xuan Y, Gill G . Direct binding of CoREST1 to SUMO-2/3 contributes to gene-specific repression by the LSD1/CoREST1/HDAC complex. Mol Cell. 2009; 34(2):145-54. PMC: 2727917. DOI: 10.1016/j.molcel.2009.03.013. View

17.

Quinlan K, Verger A, Kwok A, Lee S, Perdomo J, Nardini M . Role of the C-terminal binding protein PXDLS motif binding cleft in protein interactions and transcriptional repression. Mol Cell Biol. 2006; 26(21):8202-13. PMC: 1636740. DOI: 10.1128/MCB.00445-06. View

18.

Molloy D, Barral P, Gallimore P, Grand R . The effect of CtBP1 binding on the structure of the C-terminal region of adenovirus 12 early region 1A. Virology. 2007; 363(2):342-56. DOI: 10.1016/j.virol.2007.01.039. View

19.

Tadjuidje E, Wang T, Pandey R, Sumanas S, Lang R, Hegde R . The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone. PLoS One. 2012; 7(4):e34806. PMC: 3335822. DOI: 10.1371/journal.pone.0034806. View

20.

Subramanian T, Zhao L, Chinnadurai G . Interaction of CtBP with adenovirus E1A suppresses immortalization of primary epithelial cells and enhances virus replication during productive infection. Virology. 2013; 443(2):313-20. PMC: 3732182. DOI: 10.1016/j.virol.2013.05.018. View